export default function LiraglutideOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Liraglutide was the GLP-1 drug that proved the concept &mdash; it&rsquo;s FDA-approved, backed by a landmark heart outcomes trial, and has a decade of real-world safety data. The honest truth in 2025: weekly semaglutide produces roughly twice the weight loss with one injection a week instead of daily, and tirzepatide produces three times the weight loss at the same weekly cadence. If you&rsquo;re already on liraglutide and it&rsquo;s working, that history has value. If you&rsquo;re starting fresh, the comparison matters.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Weight Loss Comparison Shopper &mdash; Evaluating GLP-1 Options</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;My doctor brought up Saxenda for weight loss but I keep hearing about Ozempic and Wegovy. Is there a real difference or are these all basically the same thing?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It works &mdash; just not as much as the newer options</strong><br />Liraglutide suppresses appetite through the same pathway as semaglutide: it activates a receptor in the brain that signals fullness and slows the rate at which your stomach empties. People feel genuinely less hungry and eat less. In the major clinical trial, people lost about 8% of their body weight over 56 weeks &mdash; which is real and clinically meaningful weight loss for most people.</li>
          <li><strong>The cardiovascular safety data is the most established in the class</strong><br />The LEADER trial followed over 9,000 people with type 2 diabetes and cardiovascular disease for nearly four years. Liraglutide reduced the risk of heart attack, stroke, and cardiovascular death by 13% compared to placebo. That was published in 2016, and it&rsquo;s still one of the most rigorous datasets on GLP-1 heart outcomes. If long-term safety track record matters to you, liraglutide has more years of follow-up than the newer drugs.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The weight loss comparison is the defining issue: semaglutide (Wegovy) produces about 15% weight loss with one injection per week; tirzepatide (Zepbound) produces about 22% with one injection per week. Liraglutide produces about 8% with a daily injection. That&rsquo;s a meaningful efficacy gap at a higher injection frequency. If your goal is significant weight loss, the first conversation with your doctor should honestly address whether a daily injection for half the result makes sense when weekly options are available. Net: proven drug, proven mechanism, outclassed on efficacy-per-injection-burden by the next generation.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; GLP-1 Tools and Body Composition</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;m training seriously and I&rsquo;ve been thinking about using a GLP-1 drug to cut fat while preserving muscle. Is liraglutide still a reasonable choice or should I be looking at something newer?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The appetite suppression is real and can support a quality cut</strong><br />GLP-1 drugs work for fat loss primarily by reducing how much you want to eat, not by magically burning fat. For an athlete who&rsquo;s struggling to maintain a consistent caloric deficit without constant hunger, that pharmacological suppression of appetite can be the tool that makes a cut sustainable. The mechanism is well understood and the effect on caloric intake is real.</li>
          <li><strong>Daily dosing gives you more control over timing and dose adjustments</strong><br />Some athletes prefer daily dosing because if side effects are bad, you have faster flexibility than waiting a week for a weekly injection to wear off. The titration happens in weekly increments, so you can stay at a dose that controls side effects before escalating. This is a genuine practical consideration, not just a consolation prize for lower efficacy.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">GLP-1 drugs suppress appetite broadly &mdash; which means if you&rsquo;re not deliberately maintaining adequate protein and resistance training volume, lean mass loss alongside fat loss is a real risk. The drug doesn&rsquo;t know you want to preserve muscle; that still requires intentional nutrition and training. For a performance athlete evaluating GLP-1 options today, semaglutide&rsquo;s weekly convenience and ~15% weight loss ceiling versus liraglutide&rsquo;s daily injection and ~8% ceiling is a genuine choice point. Net: the mechanism works for athletes; the comparative efficacy disadvantage relative to weekly agents is real and matters.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Metabolic Health Biohacker &mdash; GLP-1 Pharmacology and What the First Generation Taught Us</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to understand what liraglutide&rsquo;s LEADER trial actually demonstrated and how its pharmacology compares to semaglutide at the receptor level &mdash; same target, but clearly not the same drug.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why it&rsquo;s worth understanding</p>
        <ol className="reta-overview__profile-why">
          <li><strong>LEADER established the cardiovascular outcomes template for the class</strong><br />Before LEADER, we knew GLP-1 drugs lowered blood sugar. LEADER proved they could also reduce cardiovascular events in high-risk patients &mdash; a fundamentally different regulatory and clinical bar. That 2016 result changed the guidelines and set the expectation that every new GLP-1 drug would need to demonstrate cardiovascular safety. SELECT (semaglutide) and SURMOUNT-MMO (tirzepatide) followed in that lineage. Understanding LEADER explains why cardiovascular outcome trials became central to GLP-1 drug development.</li>
          <li><strong>The potency and half-life differences between liraglutide and semaglutide explain the efficacy gap</strong><br />Liraglutide binds the same receptor as semaglutide but has a shorter half-life (13 hours vs. ~7 days for semaglutide). Semaglutide&rsquo;s structural modifications include a fatty acid chain that binds albumin, dramatically extending its persistence. That longer receptor engagement translates to stronger and more sustained appetite suppression &mdash; which is the primary driver of the efficacy difference. Same receptor, fundamentally different exposure kinetics.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">For a new patient start in 2025, liraglutide is a harder case to make than it was in 2015. The drug class it pioneered has been superseded by more effective agents at the same or lower injection frequency. The long safety track record is real but not uniquely valuable in the context of semaglutide now having the SELECT trial data. The interesting biohacker question is whether the dose-response curve and half-life differences produce meaningfully different side effect profiles that matter for specific individuals &mdash; and there, the answer is nuanced. Net: foundational to understanding the class; not the optimal choice for most new starts today.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Liraglutide is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not equivalent to semaglutide or tirzepatide on efficacy &mdash; roughly half the weight loss at higher injection frequency</li>
              <li>Not a muscle-preserving drug on its own &mdash; adequate protein and resistance training are still required to protect lean mass</li>
              <li>Not safe in people with a personal or family history of thyroid C-cell cancer (MEN2) &mdash; class contraindication that applies to all GLP-1 agonists</li>
              <li>Not permanent in its effects &mdash; most of the lost weight returns within a year of stopping, regardless of which GLP-1 drug you used</li>
              <li>Not the automatic best choice for a new start &mdash; the comparison to weekly semaglutide and tirzepatide needs to be an explicit part of the decision</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>The LEADER trial cardiovascular outcome data is among the most robust in the GLP-1 class &mdash; real, long-follow-up human evidence</li>
              <li>The drug that proved GLP-1 could reduce cardiovascular events, not just blood sugar &mdash; a landmark result that changed the entire class trajectory</li>
              <li>A decade of real-world safety data in millions of patients &mdash; the longest clinical experience of any GLP-1 agonist</li>
              <li>Understanding liraglutide&rsquo;s half-life and receptor pharmacology explains why semaglutide is more potent &mdash; it&rsquo;s the baseline that illuminates the improvements</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
